Technetium 99m evuzamitide - Attralus
Alternative Names: 99mTc-p5+14; AT-05Latest Information Update: 24 Jul 2023
At a glance
- Originator Attralus
- Class Diagnostic conjugates; Heavy metals; Imaging agents; Peptide diagnostics; Radioisotopes; Radiopharmaceutical diagnostics; Technetium compounds
- Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Amyloidosis
Most Recent Events
- 19 Jul 2023 Phase-I clinical trials in Amyloidosis (Diagnosis) in USA (IV) (NCT05951816)
- 17 Oct 2022 AT 05 is available for licensing as of 17 Oct 2022. https://attralus.com/pipeline
- 17 Oct 2022 Preclinical trials in Amyloidosis (Diagnosis) in USA (IV) (Attralus pipeline, October 2022)